Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 80.00 GBp
Change Today 0.00 / 0.00%
Volume 7.1K
AGL On Other Exchanges
As of 8:20 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

angle plc (AGL) Snapshot

80.00 GBp
Previous Close
80.00 GBp
Day High
80.00 GBp
Day Low
80.00 GBp
52 Week High
05/12/15 - 107.50 GBp
52 Week Low
01/26/15 - 53.75 GBp
Market Cap
Average Volume 10 Days
-0.08 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGLE PLC (AGL)

Related News

No related news articles were found.

angle plc (AGL) Related Businessweek News

No Related Businessweek News Found

angle plc (AGL) Details

ANGLE plc, a medical diagnostic company, provides cancer diagnostics and foetal health products, and management services primarily in the United Kingdom. The company’s lead product includes Parsortix cell separation device, which captures very rare circulating tumor cells in cancer patient blood. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer for personalized cancer care. ANGLE plc was founded in 2004 and is based in Guildford, the United Kingdom.

Founded in 2004

angle plc (AGL) Top Compensated Officers

Founder, Group Chief Executive and Director
Total Annual Compensation: 458.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 153.0K GBP
Compensation as of Fiscal Year 2014.

angle plc (AGL) Key Developments

Barts Cancer Institute Publishes its Work in Prostate Cancer Patients Using Angle's Parsortix System

ANGLE plc announced that Barts Cancer Institute (BCI) has published its work in prostate cancer patients using ANGLE's Parsortix system in the PLOS ONE Journal a peer-reviewed, open-access resource from the Public Library of Science. Key findings in the publication include: Using the Parsortix system, BCI researchers were able to successfully harvest cancer cells from 100% of the patients for analysis; The Parsortix system harvested a range of different circulating cells comprising not only epithelial cells, which can be captured by antibody-based systems, but also mesenchymal cells and cell clusters; The purity of the cells harvested by the Parsortix system was three times higher than the best antibody-based system studied; The cells harvested by the Parsortix system are clinically relevant and offer the potential for the Parsortix system to be used to provide a repeatable, non-invasive liquid biopsy for prostate cancer patients; The cells harvested by the Parsortix system are viable and it is possible to culture the cells, growing the cancer outside the patient; Compared to traditional antibody-based systems, the Parsortix system is quicker, easier to use, does not use expensive reagents, captures a wider range of clinically relevant cells and avoids the problems in downstream analysis caused by contaminating magnetic beads; and circulating tumour cells (CTCs) captured by the Parsortix system hold much more genetic/molecular information than cell-free DNA. Consequently CTC analysis has the potential to become the main diagnostic tool for real-time personalised treatment in prostate cancer.

ANGLE Plc Announces Breast Cancer Liquid Biopsy Results Presented at World CDx Conference in Boston

ANGLE Plc announced that the University of Southern California (USC) Norris Comprehensive Cancer Center will present highly promising results from the first phase of its work with ANGLE's Parsortix system on a liquid biopsy for breast cancer. Dr. Julie E. Lang, M.D., F.A.C.S., Associate Professor of Surgery, specialising in breast cancer and notably in molecular profiling of circulating tumor cells (CTCs) in breast cancer, will present results from USC's work with ANGLE's Parsortix system at September 9, 2015 World CDx Conference in Boston. USC have compared the RNA molecular results of a liquid biopsy using the Parsortix system (simple blood test) with those from the biopsy of metastatic sites (the secondary cancer locations) in metastatic breast cancer patients. The main findings from the first four patients are as follows: In all of the patients analysed, the Parsortix system provided highly enriched CTCs suitable for rare cell amplification and RNA Seq analysis to detect relevant biomarkers and potentially discover novel biomarkers in breast cancer. The CTCs for the Parsortix liquid biopsy had similar patterns of gene expression to the traditional biopsy of cancer cells from metastatic sites. There was some degree of heterogeneity in the CTCs, which suggests they may provide additional clinical information beyond that found at a single metastatic site and may be representative of multiple metastatic sites. Metastatic biopsies are invasive, often requiring surgery, and therefore can cause the patient considerable additional complications. The Parsortix system offers the potential to replace the metastatic biopsy for breast cancer with a simple blood test that can be repeated as often as needed, thereby providing "real-time" information for therapy selection reflecting disease progression. The next phase of the work will complete analysis for the remaining patient cohort and investigate the profiling of CTCs' biology sequentially over time to support treatment decisions in relation to HER2 directed therapy, chemotherapy, and endocrine therapy. Liquid biopsy using the Parsortix system may enable physicians to make more informed treatment decisions for women with breast cancer, ensuring that they are given therapies that will benefit them and not given therapies which will not. The Parsortix liquid biopsy may also identify novel treatment targets for new drugs in the future.

ANGLE Plc Announces Audited Consolidated Results for the Year Ended 30 April 2015

ANGLE Plc announced audited consolidated results for the year ended 30 April 2015. For the period, the company reported loss from continuing operations of £3.9 million against £2.2 million a year ago, reflecting planned investment. Loss before tax from continuing operations was £3.9 million against £2.2 million a year ago. Loss for the year was £3.89 million against £1.24 million a year ago. Loss attributable to owners of the parent from continuing operations was £3.58 million against £2.02 million a year ago. Basic and diluted loss per share from continuing operations was 8.12 pence against 4.87 pence a year ago. Basic and diluted loss per share was 8.16 pence against 2.74 pence a year ago. Net cash used in operating activities was £3.42 million against £1.91 million a year ago. Purchase of property, plant and equipment was £0.325 million against £0.083 million a year ago. Purchase of intangible assets was £0.105 million against £0.270 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGL:LN 80.00 GBp 0.00

AGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGL.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGLE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at